Galderma, a healthcare company that specialises in aesthetics and skin health solutions, has acquired exclusive rights to develop, promote and distribute botulinum toxin type A product Dysport from Ipsen, a specialty biotechnological group, in the APAC territory.
Dysport is a neuromuscular blocking toxin that can block acetylcholine release at motor nerve ends and reduce muscular spasm. The product is marketed as Dysport for medical and aesthetic markets and, in the EU, as Azzalure in an aesthetic proposition.
Ipsen’s Chairman and CEO Marc de Garidel spoke of his confidence that Galderma will be able to maximise Dysport’s aesthetic potential in the APAC region. He said: “We are delighted to further expand our collaboration with Galderma, our key historical partner for the distribution of Dysport/Azzalure in aesthetics. Our partnership now covers the majority of the global neurotoxin aesthetic market. Galderma has successfully grown Dysport and Azzalure in aesthetics, while Ipsen’s core strategy has been to reinforce its presence in movement disorders.”
Stuart Raetzman, CEO of Galderma Pharma, added: “The expansion of Galderma’s partnership with Ipsen makes both companies even better partners for healthcare professionals, and allows us to meet the needs of both physicians and patients in Asia-Pacific over many indications. These new contracts are the continuation of a very successful partnership over the last years between Galderma and Ipsen.”
Galderma and Ipsen started working together in 2007 for the commercialisation of Azzalure in Europe. At the same time, it expanded its reach for Dysport to Mexico, Brazil, Argentina and Australia. In 2014, the two companies confirmed their intent to remain partners until 2036 and expanded its coverage of the US and Canada.